RNO-27.6% . How were Rhinomed's earnings last quarter? Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). Companies with negative earnings receive an "NE." Rhinomed is an airway technology company that seeks to radically improve the way people breathe, sleep, maintain their health and take medication. The company was founded on February 9, 2004 and is headquartered in Cremorne, Australia. Latest Share Price and Events.
Registration on or use of this site constitutes acceptance of our Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today released the Appendix 4E Preliminary Final Report Read More; BUSINESS UPDATE – JUNE QUARTER CASH FLOW REPORT.
The company can report record recognised revenues for FY18 Q4 of … AU Market. Price/Cash Flow: Latest closing price divided by the last 12 months revenue/cash flow per share. The Pronto technology is a Vapor Inhaler, which opens the nose to improve airflow and delivers the soothing vapors from essential oils. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rhinomed.
Share Price & News. View which stocks have been most impacted by Coronavirus. Stable Share Price: RNO has not had significant price volatility in the past 3 months.
It operates through Turbine, Mute and Pronto technology. If a company chooses to publish the data, it’s usually once a year in their Annual Report.All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).The Top 20 Shareholders of RNO hold 68.02% of shares on issue.It's not possible to publish a real-time Top 20 Shareholder list. Market Performance. Rhinomed Ltd. is medical technology company, which engages in the identification, acquisition, and commercialization of stage therapeutic delivery technologies. Join the HotCopper ASX share market forum today for free. The Mute technology, a nasal technology that is designed to improve sleep by breathing more and snoring less.
Company finalised design and commenced production of two new products - Pronto Clear and Pronto Sleep. The price of 0.08 AUD on the exchange Sydney equals a price of 0.06 USD at the current exchange rate for AUD/USD. 0.4%. Companies are not obliged to report this data. Price/Earnings: Latest closing price divided by the earnings-per-share based on the trailing 12 months. AU Market. Rhinomed Limited (RNO) is involved in research, development and commercialisation of consumer and medical devices. . Rhinomed Limited (RNO) is involved in research, development and commercialisation of consumer and medical devices.
Company finalised design and commenced production of two new products - Pronto Clear and Pronto Sleep. Company finalised design and commenced production of two new products - Pronto Clear and Pronto Sleep. Rhinomed is an airway technology company that seeks to radically improve the way people breathe, sleep, maintain their health and take medication. Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today announced a pivotal year of growth and milestone achievement. The new Pronto range delivers combined natural stenting of the nose with a proprietary formulation of natural essential oils.Rhinomed Limited (RNO) is involved in research, development and commercialisation of consumer and medical devices. Rhinomed is an airway technology company that seeks to radically improve the way people breathe, sleep, maintain their health and take medication. Since then, RNO stock has decreased by 33.6% and is now trading at A$0.07. Please report any errors.It's not possible to publish a real-time Shareholder Distribution list. Rhinomed Stock Key Figures MORE Market Cap (USD) Company finalised design and commenced production of two new products - Pronto Clear and Pronto Sleep. Over the past six months, the relative strength of its shares against the market has been -57.68%. See the RNO directors must report any change in shareholding to the ASX within 5 business days.Data is manually extracted from 3Y Announcements. Rhinomed's stock was trading at A$0.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. The ASX Group's activities span primary and secondary market services, including capital formation and hedging, trading and price discovery (Australian Securities Exchange) central counter party risk transfer (ASX Clearing Corporation); and securities settlement for both the equities and fixed income markets (ASX Settlement Corporation).
Beach Trips From Cartagena, New Zealand Bull Kelp, Elko City Council Meeting, How Do I Contact Caa Agency, Fish Of Southwest Florida, Plain White T-shirt, Nutricurls Cleansing Conditioner, Whitsett Nc To Greensboro Nc, Afton Chemical News,
